Navigation Links
Micromet's Blinatumomab Induces Durable Remissions in Patients with Relapsed Non-Hodgkin's Lymphoma
Date:6/14/2010

BETHESDA, Md., June 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced the presentation of updated results from a Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin's lymphoma (NHL).  A high objective response rate was maintained among patients treated with blinatumomab using an adapted schedule, comparable to that previously reported in patients receiving constant dosing.  Blinatumomab is the first in a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.

The findings were presented on June 12, 2010 in an oral presentation (abstract # 0559) at the 15th Annual Congress of the European Hematology Association (EHA) in Barcelona, Spain.

"Blinatumomab continues to demonstrate a long duration of response in heavily pre-treated non-Hodgkin's lymphoma patients," said Professor Ralph Bargou, Division of Hematology and Oncology, Department of Internal Medicine II, Wuerzburg University Hospital, and the study's principal investigator. "Results of the expanded Phase 1 experience suggest that blinatumomab has the potential to alter the clinical course of disease in patients with a variety of NHL sub-types."

Phase 1 Study Design

This multi-center Phase 1 study evaluates the safety and tolerability of blinatumomab in adult patients with relapsed non-Hodgkin's lymphoma (NHL).  The key objectives of the study are to assess safety and tolerability, pharmacokinetics, pharmacodynamics, and anti-lymphoma activity. &#
'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D Day
2. Final Data from Phase 2 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
3. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
4. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
5. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
6. Clinical Data Published in Science Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab
7. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
8. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
9. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
10. Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies
11. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... OAKS, Calif. , July 24, 2014 Amgen ... report its second quarter financial results on Tuesday, July 29, ... announcement will be followed by a conference call with the ... from Amgen will be Robert A. Bradway , chairman ... management team. Live audio of the conference call ...
(Date:7/24/2014)... BUENA, N.J., July 24, 2014  IGI Laboratories, Inc. (NYSE ... and manufacturing company, announced its financial results for the second ... Highlights , Total revenues of $6.5 million in ... the same quarter in 2013 , Total revenues of ... an increase of 78% over the same period in 2013 ...
(Date:7/24/2014)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) ... development and commercialization of prescription ophthalmic pharmaceuticals, today announced ... year 2014 financial results after the market close on ... follow on the same day at 4:30 p.m. ET. ... by Dan Myers , President and Chief Executive ...
Breaking Medicine Technology:Amgen Announces Webcast of 2014 Second Quarter Financial Results 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7Alimera Sciences To Release Second Quarter 2014 Results 2
(Date:7/25/2014)... The European Society for Medical Oncology (ESMO), the ... expressed concern that the proposed EU General Data ... and add a significant burden to both doctors ... the regulation [2] stipulates ,explicit and specific patient ... patients every single time research is planned in ...
(Date:7/25/2014)... Yisrayl Hawkins, Pastor and Overseer of The House of Yahweh ... revealing to the whole world, including even the most devout ... in his new article. , Yisrayl says it all started ... by the Catholic Church. He says this plan included removing ... and replacing it with titles such as Lord and God. ...
(Date:7/25/2014)... 2014 According to the Addict Him To ... comprehensive dating guide that teaches women how to get the ... reveals in its review that this book consists of 4 ... your man won’t commit yet (and what to do about ... want you ,     Part 3: How to touch ...
(Date:7/25/2014)... At World T.E.A.M. Sports’ Adventure ... participating developmentally-disabled teens and young adults discovered that outdoor ... canoeing and hiking can be challenging. , The third-year ... Chesapeake and Ohio Canal National Historical Park , ... and able-bodied. Under slightly overcast skies and temperatures in ...
(Date:7/24/2014)... A few weeks have passed since USA Track ... by Inika McPherson is a feat to continue celebrating. ... Championships hosted the best track and field athletes competing ... Nationals with the 2nd best jump in the world ... height over head jump in history. , Zensah® is ...
Breaking Medicine News(10 mins):Health News:Is Europe putting cancer research at risk? 2Health News:Yisrayl Hawkins Says You Have Been Tricked Into Worshipping Satan in New Article 2Health News:Addict Him To You Pdf Review Exposes Mirabelle Summers' Dating Guide – Vkool.com 2Health News:Addict Him To You Pdf Review Exposes Mirabelle Summers' Dating Guide – Vkool.com 3Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 2Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 3Health News:Setting A New High Jump World Record In Zensah® Compression 2Health News:Setting A New High Jump World Record In Zensah® Compression 3
... with chronic obstructive pulmonary disease (COPD) who are hospitalized ... decreased mortality when compared to those who are not ... almost 16,000 COPD patients admitted to VA hospitals. ... edition of the American Thoracic Society,s American Journal ...
... FRIDAY, April 15 (HealthDay News) -- Is estrogen breast cancer,s ... Journal of the American Medical Association , which analyzed data ... when it found a reduced risk of breast cancer in ... This seemed to contradict years of cautions that estrogen therapy ...
... , FRIDAY, April 15 (HealthDay News) -- Losing weight can ... obese, but not all diet plans are effective in lowering ... against cancer are those that encourage long-term changes in eating ... food groups, explained Daxaben Amin, a senior clinical dietitian in ...
... New York, N.Y. (April 15, 2011) A comprehensive ... Autism Tissue Program (ATP), a postmortem brain tissue donation ... autism also had epilepsy, and co-morbidity data from the ... than expected rate of mortality in individuals with both ...
... HealthDay Reporter , THURSDAY, April 14 (HealthDay News) -- Seniors ... with their neighbors stand a much better chance of surviving ... each increase in what researchers call neighborhood "cohesion," such as ... on a neighbor for help, the odds of survival after ...
... elective surgery reduces potentially serious kidney complications, according to ... Journal of the American Society Nephrology (JASN). ... surgeries are performed around the world. Unfortunately, many patients ... surgery, often due to decreased blood flow to the ...
Cached Medicine News:Health News:Large study finds ICS therapy reduces pneumonia mortality 2Health News:Estrogen's Role in Breast Cancer Can Fluctuate 2Health News:Estrogen's Role in Breast Cancer Can Fluctuate 3Health News:A Good Diet Includes Many Cancer-Fighting Foods: Expert 2Health News:Mortality rate is increased in persons with autism who also have epilepsy 2Health News:Close-Knit Neighborhoods Raise Chances of Stroke Survival 2Health News:Statins may protect against kidney complications following elective surgery 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: